These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 19192387)
1. Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1. Park J; Oh Y; Chung KC BMB Rep; 2009 Jan; 42(1):6-15. PubMed ID: 19192387 [TBL] [Abstract][Full Text] [Related]
2. Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation. Jung MS; Park JH; Ryu YS; Choi SH; Yoon SH; Kwen MY; Oh JY; Song WJ; Chung SH J Biol Chem; 2011 Nov; 286(46):40401-12. PubMed ID: 21965663 [TBL] [Abstract][Full Text] [Related]
3. [Molecular Mechanism Underlying Abnormal Differentiation of Neural Progenitor Cells in the Developing Down Syndrome Brain]. Kurabayashi N; Sanada K Yakugaku Zasshi; 2017; 137(7):795-800. PubMed ID: 28674289 [TBL] [Abstract][Full Text] [Related]
4. Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. Park J; Oh Y; Yoo L; Jung MS; Song WJ; Lee SH; Seo H; Chung KC J Biol Chem; 2010 Oct; 285(41):31895-906. PubMed ID: 20696760 [TBL] [Abstract][Full Text] [Related]
5. Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome. Park J; Yang EJ; Yoon JH; Chung KC Mol Cell Neurosci; 2007 Oct; 36(2):270-9. PubMed ID: 17720532 [TBL] [Abstract][Full Text] [Related]
6. Regulator of calcineurin 1 (RCAN1) facilitates neuronal apoptosis through caspase-3 activation. Sun X; Wu Y; Chen B; Zhang Z; Zhou W; Tong Y; Yuan J; Xia K; Gronemeyer H; Flavell RA; Song W J Biol Chem; 2011 Mar; 286(11):9049-62. PubMed ID: 21216952 [TBL] [Abstract][Full Text] [Related]
7. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555 [TBL] [Abstract][Full Text] [Related]
8. Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration. Branchi I; Bichler Z; Minghetti L; Delabar JM; Malchiodi-Albedi F; Gonzalez MC; Chettouh Z; Nicolini A; Chabert C; Smith DJ; Rubin EM; Migliore-Samour D; Alleva E J Neuropathol Exp Neurol; 2004 May; 63(5):429-40. PubMed ID: 15198122 [TBL] [Abstract][Full Text] [Related]
9. Commonality in Down and fetal alcohol syndromes. Solzak JP; Liang Y; Zhou FC; Roper RJ Birth Defects Res A Clin Mol Teratol; 2013 Apr; 97(4):187-97. PubMed ID: 23554291 [TBL] [Abstract][Full Text] [Related]
10. Cooperation to amplify gene-dosage-imbalance effects. de la Luna S; Estivill X Trends Mol Med; 2006 Oct; 12(10):451-4. PubMed ID: 16919501 [TBL] [Abstract][Full Text] [Related]
11. Increased dosage of DYRK1A and DSCR1 delays neuronal differentiation in neocortical progenitor cells. Kurabayashi N; Sanada K Genes Dev; 2013 Dec; 27(24):2708-21. PubMed ID: 24352425 [TBL] [Abstract][Full Text] [Related]
12. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients]. Asai M; Kawakubo T; Mori R; Iwata N Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290 [TBL] [Abstract][Full Text] [Related]
13. Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. Head E; Lott IT; Patterson D; Doran E; Haier RJ J Alzheimers Dis; 2007 Mar; 11(1):61-76. PubMed ID: 17361036 [TBL] [Abstract][Full Text] [Related]
14. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome. Wegiel J; Kaczmarski W; Barua M; Kuchna I; Nowicki K; Wang KC; Wegiel J; Yang SM; Frackowiak J; Mazur-Kolecka B; Silverman WP; Reisberg B; Monteiro I; de Leon M; Wisniewski T; Dalton A; Lai F; Hwang YW; Adayev T; Liu F; Iqbal K; Iqbal IG; Gong CX J Neuropathol Exp Neurol; 2011 Jan; 70(1):36-50. PubMed ID: 21157379 [TBL] [Abstract][Full Text] [Related]
15. Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome. Granese B; Scala I; Spatuzza C; Valentino A; Coletta M; Vacca RA; De Luca P; Andria G BMC Med Genomics; 2013 Jul; 6():24. PubMed ID: 23830204 [TBL] [Abstract][Full Text] [Related]
16. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice. Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917 [TBL] [Abstract][Full Text] [Related]
17. NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect. Stefos GC; Soppa U; Dierssen M; Becker W PLoS One; 2013; 8(6):e67470. PubMed ID: 23825664 [TBL] [Abstract][Full Text] [Related]
18. Protein kinase A phosphorylates Down syndrome critical region 1 (RCAN1). Kim SS; Oh Y; Chung KC; Seo SR Biochem Biophys Res Commun; 2012 Feb; 418(4):657-61. PubMed ID: 22293192 [TBL] [Abstract][Full Text] [Related]
19. Dyrk1A-mediated phosphorylation of RCAN1 promotes the formation of insoluble RCAN1 aggregates. Song WJ; Song EA; Choi SH; Baik HH; Jin BK; Kim JH; Chung SH Neurosci Lett; 2013 Oct; 554():135-40. PubMed ID: 24021800 [TBL] [Abstract][Full Text] [Related]
20. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Altafaj X; Dierssen M; Baamonde C; Martí E; Visa J; Guimerà J; Oset M; González JR; Flórez J; Fillat C; Estivill X Hum Mol Genet; 2001 Sep; 10(18):1915-23. PubMed ID: 11555628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]